Log in

Pharmacy: Thermo Fisher Scientific to buy Patheon 7,2 billion dollars

The American manufacturer of scientific equipment Thermo Fisher Scientific said Monday it has agreed to acquire the pharmaceutical outsourcing group Patheon to 7,2 billion, including debt.

Patheon, pharma supplier and biotechnology employs 9.000 people worldwide and generated in 2016 a turnover of 1,9 billion.

The company, according to Thermo Fisher is particularly specialized in the growing market of manufacturing and development outsourcing.

"By offering both solutions development and manufacturing for small and large molecules, the company helps customers reduce the time and costs of the drugs market," said the statement.

Thermo Fisher, which already provides pharmacy sector of the business facilities for research, clinical trials and production, and its range of products.

The agreement provides for a price per share 35 Patheon, which represents a premium of nearly 35% premium over Friday's stock exchange. The transaction is expected to close by the end of the year.

Patheon, which had merged with the Dutch chemical group DSM 2014, made its debut at the New York Stock Exchange in 2016.

a3p-100pxhaut logo


Commit to share
Transmit and progress together
Promoting innovation

The A3P Association is a major player in the pharmaceutical and biotechnology industry.
Created in 1986, it contributes to the good development of the production of medicines and clean and sterile equipment, it runs a network of professionals 21 000, manufacturers and suppliers, as part of International Congress and technical days.

It now has over 1700 members who share their technical experience, scientific and regulatory.

More info on video (Versiongb here )

  group    administrators A3P
& Project Managers

letter   newsletter A3P